A Look At Zevra Therapeutics (ZVRA) Valuation As MIPLYFFA Patent Extension Targets 2041 Exclusivity

Simply Wall St.06-10

Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642424597?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-06-10 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642424597","market":"nz","top_or_hot":-1,"title":"A Look At Zevra Therapeutics (ZVRA) Valuation As MIPLYFFA Patent Extension Targets 2041 Exclusivity","media":"Simply Wall St.","content":"<div>\n<p>Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/a-look-at-zevra-therapeutics-zvra-valuation-as-miplyffa-pate\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Zevra Therapeutics (ZVRA) Valuation As MIPLYFFA Patent Extension Targets 2041 Exclusivity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Zevra Therapeutics (ZVRA) Valuation As MIPLYFFA Patent Extension Targets 2041 Exclusivity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-10 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/a-look-at-zevra-therapeutics-zvra-valuation-as-miplyffa-pate><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/a-look-at-zevra-therapeutics-zvra-valuation-as-miplyffa-pate\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZVRA","symbol_name":"Zevra Therapeutics","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/a-look-at-zevra-therapeutics-zvra-valuation-as-miplyffa-pate","article_id":"2642424597","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zvra/zevra-therapeutics/news/a-look-at-zevra-therapeutics-zvra-valuation-as-miplyffa-pate","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2642424597","pubTimestamp":1781097910,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending exclusivity through 2041.\nSee our latest analysis for Zevra Therapeutics.\nThe Orange Book patent move has arrived alongside strong momentum, with Zevra’s share price delivering a 63.79% year to date return and a 31.22% 90 day share price return. The 3 year total shareholder return of 134.71%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZVRA":"Zevra Therapeutics","BK4007":"制药"},"translate_title":"MIPLYFFA专利延期目标为2041年排他性，看看Zevra Therapeutics(ZVRA)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZVRA":1.5},"content_text":"Zevra Therapeutics (ZVRA) is back in focus after requesting that a new patent for its approved Niemann Pick type C treatment MIPLYFFA be added to the FDA’s Orange Book, with the goal of extending exclusivity through 2041. See our latest analysis for Zevra Therapeutics. The Orange Book patent move has arrived alongside strong momentum, with Zevra’s share price delivering a 63.79% year to date return and a 31.22% 90 day share price return. The 3 year total shareholder return of 134.71% contrasts with a 5 year total shareholder return that is down 8.93%. If you are looking beyond rare disease stocks, this could be a good moment to use this strength as a reference point and scan 39 healthcare AI stocks With the stock up sharply this year, trading at a value score of 6 and at a large discount to average analyst targets and intrinsic estimates, is Zevra still undervalued, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 47.5% Undervalued With Zevra trading at $13.66 against a narrative fair value of $26.00, the most widely followed view highlights a large gap between price and potential.  With $217.7 million in nondilutive capital and an SG&A infrastructure that is already at critical mass, Zevra is competitively positioned to accelerate clinical development, pursue new in-licensed assets, and capture additional pipeline growth opportunities without new financing, enabling significant earnings and margin expansion from organic and inorganic growth.    Read the complete narrative. This narrative explains that valuation gap by focusing on revenue expansion, shifting margins, and a future earnings multiple that is below many peers while still implying meaningful upside. Result: Fair Value of $26.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this bullish setup can unravel if rare disease markets saturate faster than expected, or if products like OLPRUVA continue to underperform and trigger further write downs. Find out about the key risks to this Zevra Therapeutics narrative. Next Steps The mix of optimism and concern around Zevra is clear, so use that tension as a prompt to move quickly and check the company's full picture for yourself with 5 key rewards and 1 important warning sign Looking for more investment ideas? If Zevra has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.  Spot potential value early by scanning screener containing 21 high quality undiscovered gems before they attract wider attention. Prioritize resilience by reviewing 63 resilient stocks with low risk scores that may better match your comfort with volatility. Target quality at a discount by assessing 46 high quality undervalued stocks that combine fundamentals with appealing pricing.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Zevra Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642424597","isCrawlerRequest":true}